
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Recipient : Sosei Heptares
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration
Details : The collaboration combines Sosei's leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform to drive novel drug discovery for a second neurological disease target.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Recipient : Sosei Heptares
Deal Size : Undisclosed
Deal Type : Expanded Collaboration

Details : The funds will be used to develop the next generation of small molecule drugs and to advance and expand PharmEnable’s portfolio of wholly owned and co-discovery projects across oncology and neurology targets, as well as supporting further platform R&D.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 22, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Denali Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The strategic collaboration will aim to accelerate drug discovery in neurodegenerative disease, tackling undisclosed targets in a multi-year programme. Denali will be responsible for the further lead optimisation, development, and commercialisation of th...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Denali Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
